May 12 (Reuters) -

• BOEHRINGER INGELHEIM LICENSES PRECLINICAL ANTIBODY PROGRAM FROM IMMUNITAS THERAPEUTICS TO ADVANCE TREATMENTS FOR CHRONIC INFLAMMATORY DISEASES

• BOEHRINGER INGELHEIM: UNDER AGREEMENT, TO OBTAIN WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE AND COMMERCIALIZE ANTIBODY PROGRAM

• BOEHRINGER INGELHEIM: UNDER AGREEMENT IMMUNITAS THERAPEUTICS WILL RECEIVE UP TO EUR 407.5 MILLION, IN ADDITION TO TIERED ROYALTIES ON FUTURE SALES

Source text: ID:nGNX7v40ZX